¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Secondary malignant neoplasm of other specified sites"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® neoplasm ÇÑ±Û ½Å»ý¹°
¼³¸í   
  »õ·Î »ý±ä ¹°ÁúÀ̶ó´Â ¶æÀÌ´Ù. À̰ÍÀº ´Ù¸¥ ¸»·Î ¡°Á¾¾ç(tumor)¡±À̶ó°íµµ Çϴ µ¥, ½ÇÁ¦·Î À̵éÀÇ ¸íÈ®ÇÑ ¶æÀº ¼­·Î ´Ù¸£´Ù. Á¾¾çÀ̶ó´Â ¸»Àº ¡°±× Å©±â°¡ 1cm°¡ ³Ñ´Â ÀÏÁ¾ÀǠȤ¡±À» ¸»Çϴ °ÍÀ¸·Î ÇǺΰú¿¡¼­´Â À̺¸´Ù ÀÛÀº È¤À» ±¸ÁøÀ̶ó°í ÇÏ¿© ±¸º°ÇÏ¿© ºÎ¸¥´Ù. ÇÏÁö¸¸, À̰ÍÀº ¶ÇÇÑ ÇǺλӸ¸ ¾Æ´Ï¶ó ½Åü³» ¾îµð¿¡¼­µç »ý±æ ¼ö ÀÖÀ¸¹Ç·Î ¸ðµÎ ÅëĪÇÏ¿© Á¾¾çÀ̶ó°í ºÎ¸¥´Ù. ÀÌ¿¡ ºñÇØ ¡°½Å»ý¹°¡±Àº ½Åü³» ¾ø´ø °ÍÀÌ »õ·Î »ý°Ü³µ´Ù´Â ¶æÀ¸·Î ºÙÀΠ¸»ÀÌ´Ù. ±×·¯³ª, ÀÌ µÑÀÇ °ü°è¸¦ ¸íÈ®È÷ ±ÔÁ¤ÁþÁö ¾Ê°í ÀÖÀ¸¸ç ´ë°³ °°Àº ¶æÀ¸·Î È¥¿ëµÈ´Ù.
  
  ½Å»ý¹°¿¡´Â ¡°¾ç¼º(benign)¡±°ú ¡°¾Ç¼º(malignant)¡±ÀÌ ÀÖ´Ù. ÀÌ µÑÀÇ ±¸º°Àº ¿©·¯ °¡Áö ±âÁØ¿¡ µû¸£Áö¸¸, ¶§·Î´Â ±¸º°ÀÌ ¾î·Á¿ï ¶§µµ ÀÖ´Ù. ´ë°³ ¾ç¼ºÀº »ý¸í´ÜÃàÀ» Àß ÀÏÀ¸Å°Áö ¾Ê´Â °ÍÀ¸·Î Ä¡·áÈÄ¿¡ Àç¹ßµµ Àß ÇÏÁö ¾Ê´Â´Ù. ÀÌ¿¡ ºñÇØ ¾Ç¼ºÀº Àç¹ß»Ó¸¸ ¾Æ´Ï¶ó ´Ù¸¥ ±â°üÀ¸·Î ¿Å°Ü°¡¼­ °°Àº º´º¯ÀÌ ¹ß»ýÇϴ ¡°ÀüÀÌ(metastasis)¡±Çö»óµµ ÀϾ´Ù. µû¶ó¼­ »ý¸íÀ» ´ÜÃà½Ã۴ °æ¿ì°¡ ¸¹À¸¸ç, ´ë°³ Ä¡·á°¡ ¾î·Æ´Ù.
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
¿µ¹® malignant melanoma ÇÑ±Û ¾Ç¼ºÈæ»öÁ¾
¼³¸í   
  ÇǺο¡¼­ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁַΠ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡Çϴ °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇϴ µå¹® º´À¸·Î ÇǺο͠±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼­ À¯·¡Çϴ ¾Ç¼ºÁ¾¾çÀÌ´Ù.
  
  ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀΠ°ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • benign neoplasm
    ¾ç¼ºÁ¾¾ç
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cystic neoplasm
    ³¶¼º½Å»ý¹°, ³¶¼ºÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • choroidal malignant melanoma
    ¸Æ¶ô¸·¾Ç¼ºÈæ»öÁ¾
  • malignant
    ¾Ç¼º-
  • malignant anemia
    ¾Ç¼ººóÇ÷
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó
  • malignant degeneration
    ¾Ç¼ºº¯¼º
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • cystic neoplasm
    ³¶Á¾
  • malignant
    ¾Ç¼º-
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary hemostasis
    ÀÌÂ÷ÁöÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • borderline malignant epithelial ovarian neoplasm
    °æ°è¾Ç¼º»óÇdz­¼ÒÁ¾¾ç
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • neoplasm
    ½Å»ý¹°, Á¾¾ç
  • malignant anemia
    (¢¡pernicious anemia) ¾Ç¼ººóÇ÷
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó
  • malignant degeneration
    ¾Ç¼ºº¯¼º
  • malignant reticulemic erythroderma
    ¾Ç¼º¸Á»óÈ«»öÇǺÎÁõ
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant progressive histiocytoma
    ¾Ç¼ºÁøÇàÁ¶Á÷±¸Á¾
  • malignant
    ¾Ç¼º-
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunodeficiency syndrome, secondary
    ÀÌÂ÷¼º ¸é¿ª°áÇÌ ÁõÈıº, ¼Ó¹ß¼º ¸é¿ª°áÇÌ ÁõÈıº
  • infection, secondary
    ÀÌÂ÷°¨¿°
  • process, secondary (psychic)
    ÀÌÂ÷°úÁ¤.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specified disease
    ƯÁ¤µÈ Áúº´(÷åïÒ¡­òðÜ»), ƯÀÌÁúȯ(÷åì¶òðü´)
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª).
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°(¡­ãæßæÚª)
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË).
  • cutaneous neoplasm
    ÇǺνŻý¹°, ÇǺÎÁ¾¾ç(¡­ðþåË)
  • hepatic neoplasm
    °£½Å»ý¹°(ÊÜãæßæÚª).
  • lymphoplasmacytic neoplasm
    ¸²ÇÁÇüÁú¼¼Æ÷¼º ½Å»ý¹°
  • neoplasm =neoplasma
    ½Å»ý¹° Á¾¾ç(¡­ðþåË)
  • organoid neoplasm
    ±â°ü¾ç½Å»ý¹°(ÐïίåÆãæßæÚª)
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª).
  • testis neoplasm
    °íȯ½Å»ý¹°(ÍÂü¯ãæßæÚª)
  • thyroid neoplasm
    °©»ó¼±½Å»ý¹°(¡­ãæßæÚª)
  • secondary yolk sac [secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Secondary yolk sac [Secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷³­È²³¶
  • Secondary segmental bronchus
    ±¸¿ª±â°üÁö°¡Áö
    [¿¾ ¿ë¾î] ÀÌÂ÷±¸±â°üÁö
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
  • Secondary spiral lamina
    µÑ°³ª¼±ÆÇ
    [¿¾ ¿ë¾î] Á¦2³ª¼±ÆÇ
  • Secondary fissure
    µÑ°ƴ»õ
    [¿¾ ¿ë¾î] Á¦2¿­
  • Secondary polar body
    ÀÌÂ÷±ØÃ¼
    [¿¾ ¿ë¾î] ÀÌÂ÷±ØÃ¼
  • Secondary oocyte
    ÀÌÂ÷³­¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­¸ð¼¼Æ÷
  • Secondary oocyte, Metaphase II
    ÀÌÂ÷³­¸ð¼¼Æ÷, ÀÌÂ÷°¨¼öºÐ¿­Áß±â
    [¿¾ ¿ë¾î] Á¦À̳­¸ð¼¼Æ÷,ÀÌÂ÷Áß±â
  • Secondary follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary ovarian follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary visceral nucleus
    ÀÌÂ÷³»Àå½Å°æÇÙ
    [¿¾ ¿ë¾î] Á¦2Àå½Å°æÇÙ
  • Secondary abdominal implantation
    ÀÌÂ÷¹è¾ÈÂø»ó
    [¿¾ ¿ë¾î] ÀÌÂ÷Àûº¹ºÎÂø»ó
  • Secondary bone
    ÀÌÂ÷»À
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ
  • Secondary osteon
    ÀÌÂ÷»À´ÜÀ§
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ¿ø
  • Secondary osteogenic bud
    ÀÌÂ÷»À¹ß»ý½Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÇü¼º¾Æ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amebic meningoencephalitis
    ÀÌÂ÷¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • secondary echinococcosis
    ÀÌÂ÷Æ÷ÃæÁõ
  • secondary infection
    ÀÌÂ÷°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half-of-the-sites reactivity
    ¹Ý(Úâ)ÀÚ¸® ¹ÝÀÀ¼º (Úãëëàõ)
  • splice sites
    ½ºÇöóÀ̽º ÀÚ¸®
  • switching sites
    ¾ù¹Ù²ñ ÀÚ¸®
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
  • secondary acidosis
    ÀÌÂ÷ »êÁõ(ì£ó­ß«ñø)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • secondary alkalosis
    ÀÌÂ÷(ì£ó­) ¾ËÄ®¸®Áõ(ñø)
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
  • secondary bond
    ÀÌÂ÷ °áÇÕ(ì£ó­Ì¿ùê)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary culture
    ÀÌÂ÷ ¹è¾ç(ì£ó­ÛÆå×)
  • secondary deficiency
    ÀÌÂ÷ °áÇÌ(ì£ó­ÌÀù¹)
  • secondary derived protein
    ÀÌÂ÷ À¯µµ´Ü¹éÁú(ì£ó­ë¯ÓôÓ±ÛÜòõ)
  • secondary electron
    ÀÌÂ÷ ÀüÀÚ(ì£ó­ï³í­)
  • secondary fluor
    ÀÌÂ÷ Çü±¤Á¦(ì£ó­û«ÎÃð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°
  • neoplasm
    ½Å»ý¹°
  • malignant
    ¾Ç¼ºÀÇ
  • malignant adenoma
    ¾Ç¼º¼±Á¾
  • malignant cachexia
    ¾Ç¼º¾Ç¾×Áú
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant degeneration
    ¾Ç¼ºÈ­
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • malignant polyp
    ¾Ç¼ºÆú¸³
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • secondary
    ÀÌÂ÷(¼º)ÀÇ, ¼Ó¹ß(¼º)ÀÇ
  • secondary anemia
    ¼Ó¹ß¼ººóÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary lesion
    ÀÌÂ÷¼ºº´º¯, ÀÌÂ÷¹ßÁø, ¼Ó¹ßÁø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MH malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
MHS major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
FMN first malignant neoplasm; flavin mononucleotide; frontomaxillonasal [suture]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SMN Second Malignant Neoplasm
EDNOS Eating Disorder Not Otherwise Specified
NOS Not Otherwise Specified
PDD-NOS Pervasive Developmental Disorder Not Otherwise Specified
SPF specified pathogen free
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • C79.8
    Secondary malignant neoplasm of other specified sites
    ±âŸ ¸í½ÃµÈ ºÎÀ§ÀÇ ¼Ó¹ß¼º ¾Ç¼º½Å»ý¹°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • disseminated malignant neoplasm
    ÆÛÁ® ÀÖ´Â ¾Ï
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • hematologic neoplasm
    Ç÷¾× ½Å»ý¹°
  • immunologic neoplasm
    ¸é¿ªÇÐÀû ½Å»ý¹°, ¸é¿ªÇÐÀû Á¾¾ç
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
  • borderline malignant epithelial ovarian neoplasms
    °æ°è¼º »óÇǼº ³­¼Ò Á¾¾ç
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • malignant
    ¾Ç¼º, ¾Ç¼ºÀÇ
    Á¡Â÷ÀûÀ¸·Î ³ªºüÁ®¼­ Á×À½¿¡ À̸£°Ô ÇÏ´Â. ÅðÇ༺ ħÀ±, ÀüÀÌÀÇ ¼ºÁúÀ» °¡Áö´Â Á¾¾ç¿¡ »ç¿ëµÈ´Ù.
  • malignant adenoma
    ¾Ç¼º ¼±Á¾
  • malignant anthrax
    ¾Ç¼º źÀú
  • malignant cachexia
    ¾Ç¼º ¾Ç¾×Áú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
attachment sites <microbiology, molecular biology> Particular loci in both bacterial and phage DNA molecules at which phage DNA is integrated into the bacterial DNA by recombination between these sites.
(12 Dec 1998)
binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
(12 Dec 1998)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
chromosome fragile sites Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations, and, when located on sex chromosomes, they produce phenotypic abnormalities. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus.
(12 Dec 1998)
contact sites A Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
contact sites B Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling.
(18 Nov 1997)
crohn disease: sites <radiology> Oesophagus: rare, stomach (2-20%): granulomatous gastritis, pseudo-post Bilroth-I appearance, ramshorn sign, antral-duodenal fistula, duodenum (4-10%): almost always associated with gastric involvement, bulb and proximal half of duodenum, small bowel (80%): regional enteritis, terminal ileum (alone/in combination): 95%, jejunum/ileum: 15%, commonly associated with medial caecal defect, colon (22-55%): granulomatous colitis, particularly on the right side, transverse stripe sign: contrast within coarse mucosal folds, rectum (35-50%) see: Crohn disease
(12 Dec 1998)
sequence tagged sites Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database.
(12 Dec 1998)
sequence-tagged sites Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction.
(05 Mar 2000)
immunologically privileged sites Sites where allografts are not readily rejected, probably because these particular areas have poor lymphatic drainage.
(05 Mar 2000)
antibodies, neoplasm Immunoglobulins induced by antigens specific for tumours other than the normally occurring histocompatibility antigens.
(12 Dec 1998)
antigens, neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumour cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
(12 Dec 1998)
brain neoplasm Neoplasms of the part of the central nervous system contained within the cranium.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neoplasm
    (º´¸®)ü³»¿¡ »ý±â´Â ½Å»ý¹°;(ƯÈ÷)Á¾¾ç
  • malignant
    ¾ÇÀǸ¦ ǰÀº; ¾Ç¼ºÀÇ; ¹ÝÇ×ÀÚ
  • malignant
    À¯ÇØÇÑ;¾Ç¼ºÀÇ;¾ÇÀǸ¦ ǰÀº;... (¿µ»ç) Charles I ½Ã´ëÀÇ ¿Õ´ç¿ø
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • secondary
    Á¦ 2ÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
  • post secondary education
    Áßµî °úÁ¤ ÈÄÀÇ ±³À°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á